Media Report

Fierce Pharma Asia ：Gracell's CAR-T wows, showcasing a 100% tumor response rate for its BCMA-targeted CAR-T therapy

Dec 16, 2022
ASH : In next BCMA myeloma race, Gracell dazzles with 100% response rate as Pfizer, BMS place their bets

Dec 12, 2022
Drug Development & Delivery ：Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating Treatment of B-cell Acute Lymphoblastic Leukemia

Oct 18, 2022
CGT Live ：Gracell Continues Progress in R/R B-Cell Acute Lymphoblastic Leukemia

Oct 17, 2022
Drug Development & Delivery ：Gracell Doses First Patients in First-in-Human Clinical Trial of Dual-Targeting CAR-T Therapy

Feb 18, 2022
Precision Oncology News ：Gracell Biotechnologies Begins Treating B-NHL Patients With CAR T-Cell Therapy in Trial

Feb 17, 2022
The Science Advisory Board ：Gracell Biotechnologies unveils innovation center in San Diego

Jan 13, 2022
Bloomberg: China's Gracell Biotechnologies Lists on Nasdaq

Jan 11, 2021
CNBC: No plans yet to list in China, political impact minimized: Gracell Biotechnologies CEO

Jan 11, 2021
Barron's： Biotech IPO Gracell Surge on Trading Debuts

Jan 09, 2021

1
2
3